SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 253 filers reported holding SAGE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $5,957,000 | +264.8% | 104,851 | +380.7% | 0.01% | +250.0% |
Q1 2021 | $1,633,000 | -54.9% | 21,814 | -47.9% | 0.00% | -55.6% |
Q4 2020 | $3,619,000 | -59.9% | 41,830 | -71.7% | 0.01% | -65.4% |
Q3 2020 | $9,019,000 | +1207.1% | 147,568 | +514.9% | 0.03% | +1200.0% |
Q1 2020 | $690,000 | -36.3% | 24,000 | +60.0% | 0.00% | -50.0% |
Q4 2019 | $1,083,000 | +2.9% | 15,000 | +100.0% | 0.00% | 0.0% |
Q3 2019 | $1,052,000 | -17.9% | 7,500 | +7.1% | 0.00% | -20.0% |
Q2 2019 | $1,282,000 | +34.4% | 7,000 | +16.7% | 0.01% | +25.0% |
Q1 2019 | $954,000 | -66.2% | 6,000 | -70.0% | 0.00% | -63.6% |
Q3 2018 | $2,823,000 | -23.1% | 19,989 | -14.8% | 0.01% | -26.7% |
Q2 2018 | $3,672,000 | +18.8% | 23,460 | +22.3% | 0.02% | +7.1% |
Q1 2018 | $3,090,000 | +188.5% | 19,184 | +195.1% | 0.01% | +180.0% |
Q4 2017 | $1,071,000 | +71.6% | 6,500 | -35.1% | 0.01% | +66.7% |
Q3 2017 | $624,000 | -13.0% | 10,009 | +11.1% | 0.00% | 0.0% |
Q2 2017 | $717,000 | +26.0% | 9,009 | +12.6% | 0.00% | 0.0% |
Q1 2017 | $569,000 | – | 8,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |